-transparent.png){kind=logo}
The pharmacokinetics and metabolism of quinidine were investigated in extensive and poor metabolisers of sparteine. No differences in plasma clearance, terminal half life, volume of distribution or cumulative urinary excretion of quinidine, 3-hydroxyquinidine and quinidine-N-oxide were observed between phenotypes. Thus, it is unlikely that quinidine metabolism is controlled by the sparteine/debrisoquine gene locus.
Related Publications
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
January 1991,
British journal of clinical pharmacology,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
June 1993,
Pain,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
February 1994,
The Journal of pharmacology and experimental therapeutics,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
August 2005,
European journal of clinical pharmacology,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
February 1999,
Pharmacogenetics,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
January 1996,
European journal of clinical pharmacology,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
January 1982,
European journal of clinical pharmacology,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
April 1991,
British journal of clinical pharmacology,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
January 1996,
European journal of clinical pharmacology,
G Mikus, and
H R Ha, and
S Vozeh, and
C Zekorn, and
F Follath, and
M Eichelbaum
April 1994,
British journal of clinical pharmacology,
